0. Advocacy Webpage Graphics-Narrow -Standardize It 

There are many misconceptions about the disease of addiction, and a culture change is needed in this country to drive patients to the treatment options that have proven to be effective at reducing overdose deaths and supporting patients in remission and recovery. ASAM advocates for the use of nationally recognized guidelines and standards for the treatment of addiction and the dissemination of competency-based addiction education for all healthcare professionals.





The ASAM Criteria®, the most widely used and comprehensive set of guidelines for placement, continued stay and transfer/discharge of patients with addiction and co-occurring conditions, is a fundamental tool for the standardization of addiction medicine.



 
ASAM Level of Care Cert final
 



 

Transforming the Delivery of Substance Use Disorder Treatment in States

This slide presentation describes ASAM tools and resources that can help states transform the delivery of substance use disorder treatment.

 




Featured Public Policy Statements

0. doctor patient

Regulation of Office-Based Opioid Treatment

OBOT promotes the treatment of addiction in the primary care setting, but ASAM understands that the use of controlled substances to treat addiction introduces the possibility of misuse and diversion of the very medications used for treatment.
2. medical-recordscrop

Prescription Drug Monitoring Programs (PDMPs)

Find out more about PDMPs and ASAM's recommendations on how they should be regulated.

Worldgen

Joint Public Correctional Policy Statement on the Treatment of Opioid Use Disorders for Justice Involved Individuals

Learn more about how ASAM and the American Correctional Association (ACA) are supporting the use of evidence-based practices for the treatment of opioid use disorders in correctional settings.





"By implementing a quality-driven national addiction treatment infrastructure, we can empower patients and their families with information on how to identify and access high-quality treatment."

-Kelly Clark, MD, MBA, DFASAM
Immediate-Past President of ASAM




Resources

dtd-webpage-title-banner

Appropriate Use of Drug Testing in Clinical Addiction Medicine

Provides guidance about the effective use of drug testing in the identification, diagnosis, treatment and promotion of recovery for patients with, or at risk for, addiction.

guideline-webpage-title-banner-1

The ASAM National Practice Guideline

The ASAM National Practice Guideline and associated resources provide information on evidence-based treatment of opioid use disorder.

confidentiality_472x176aa36159472bc604ca5b7ff000030b21a

Confidentiality (42 CFR Part 2)

Learn how ASAM continues to call for needed privacy protections as 42 CFR Part 2 regulations and the underlying statute are updated. 




Related News

newspapers-3488857_1920B
  • February 25, 2019

    ASAM President Testifies Before Bipartisan Congressional Task Force on Opioid Overdose Epidemic

    Dr. Kelly J. Clark, president of ASAM, participated in a congressional roundtable sponsored by the House Bipartisan Heroin and Opioid Task Force. At the event, she urged lawmakers to make strategic investments in the substance use disorder (SUD) treatment workforce in order to close the addiction treatment gap and ensure the millions of Americans living with SUD are able to receive the care they need.
  • January 10, 2019

    New Taxonomy Code

    Given the recognition of addiction medicine as a medical subspecialty by ABMS, with an established curriculum and training standards and a new certification pathway, ASAM believed it was timely and appropriate to request a new taxonomy code that would capture the distinctive nature of this area of specialty practice.
  • December 19, 2018

    ASAM Submits Comments to FDA Regarding Strategies to Increase Naloxone Availability

    ASAM submitted comments to the Food and Drug Administration (FDA) in response to a request for comment ahead of a public advisory committee meeting regarding strategies to increase the availability of naloxone products intended for use in the community.